Special Issue

Personalized Therapies and Clinical Outcomes for Older Patients with Lymphoma

Message from the Guest Editor

By 2025, people 65 years or older will comprise about 20 percent of the total population in Japan. Among older adults, the percentage of patients over 80 years old will increase in Western Europe, China, and Japan. Recently several new drugs have been developed for the treatment of diffuse large B-cell lymphoma (DLBCL), including DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab. In clinical trials, patients with a poor performance status or renal, hepatic, or bone marrow dysfunction generally have been excluded, thus raising questions about the general applicability of data derived from such trials. This is particularly true for patients over 80 years. This special issue aims to collect and publish original research articles and reviews demonstrating recent advance in our knowledge on new diagnostic and therapeutic approaches in these clinical conditions with regarding the personalization of the patient's treatment based on his clinical characteristics, comorbidities, and preference.

Guest Editor

Prof. Dr. Yamasaki Satoshi

Department of Hematology, St. Mary's Hospital, 422 Tsubukuhonmachi, Kurume 830-8543, Japan

Deadline for manuscript submissions

closed (31 December 2024)



Hematology Reports

an Open Access Journal by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



mdpi.com/si/178755

Hematology Reports Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 hematolrep@mdpi.com

mdpi.com/journal/ hematolrep





Hematology Reports

an Open Access Journal by MDPI

Impact Factor 1.2 CiteScore 1.4 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Hematology Reports (ISSN 2038-8330) is an international open access journal on all aspects of prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials.

Editor-in-Chief

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 26.9 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

